logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Impacting News

Anavex Life Sciences Reports Publication in Scientific Journal Demonstrating the Potential of Anavex®3-71 in Preventing Cognitive Decline in Alzheimer's Disease

Anavex Life Sciences NEWS Anavex Life Sciences ( AVXL )  reported a new peer reviewed publication in journal Neurobiology of Aging , titled “ Early treatment with an M1 and sigma 1 receptor agonist prevents cognitive decline in a transgenic rat model displaying Alzheimer-like amyloid pathology ", featuring the orally available small molecule ANAVEX®3-71 (...

Read More

October 26, 2023

0

Denali Therapeutics: Positive Clinical Results and Regulatory Progress for Development Programs in ALS. See Also: NTLA Tumbling Today

Denali Therapeutics News Denali Therapeutics ( DNLI ) -  a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier ( BBB ) for neurodegenerative diseases.  Denali pursues new treatments by rigorously assessing genetically validated...

Read More

October 8, 2021

0

Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in the New England Journal of Medicine

Intellia Therapeutics in the NEWS Yesterday, January 31, Intellia Therapeutics ( NTLA ) announced that the results from Phase 1 portion of the Phase 1/2 study of NTLA-2002 were published online in the New England Journal of Medicine ( NEJM...

Read More

February 1, 2024

0

Regenxbio Good News About RGX-314 for Diabetic Retinopathy

Regenxbio Announced Data from Phase 2 ALTITUDE Trial of RGX-314 for DR Regenxbio ( RGNX ) announced initial data from the ongoing Phase 2 ALTITUDE™ trial of RGX-314 for the treatment of diabetic retinopathy ( DR ) without center-involved diabetic...

Read More

October 11, 2021

0

Intellia Therapeutics and SparingVision Strategic Collaboration to Develop Novel Ocular Therapies. See Also: Crispr Therapeutics’ News is Good, Not Bad

Intellia Therapeutics and SparingVision Collaboration Intellia Therapeutics ( NTLA ) and SparingVision - a genomic medicine company developing vision saving treatments for ocular diseases, announced a strategic collaboration to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of...

Read More

October 14, 2021

0

More Good News for Neurocrine Biosciences

Neurocrine Biosciences’ Product INGREZZA Improved Chorea Associated with Huntington's Disease Through Week 50  Yesterday, November 2, 2023, Neurocrine Biosciences ( NBIX ) announced interim results from the KINECT®-HD2 study about INGREZZA® (valbenazine) capsules used for long-term treatment of adults with...

Read More

November 3, 2023

0

Regenxbio Product RGX-121 for the Treatment of MPS II Achieves Primary Endpoint

Regenxbio Product RGX-121 Achieves Primary Endpoint From Regenxbio ( RGNX ) we learned that results from the Phase I/II/III CAMPSIITE® trial of the firm’s product RGX-121 for the treatment of 5 years old patients diagnosed with Mucopolysaccharidosis Type II (...

Read More

February 9, 2024

0

Current News From Three Selected Biotech Firms

Three Biotech Firm in the NEWS Verona Pharma Verona Pharma plc ( VRNA ) announced that senior management will present a company overview at the following conferences in November 2023: Jefferies London Healthcare Conference Date: Wednesday, November 15, 2023 Time:...

Read More

November 8, 2023

0

Rocket Pharmaceuticals Inc Announces Data Updates at the ESGCT Conference for RP-L201 for the Treatment of LAD-I

Rocket Pharmaceuticals Inc Announces Successful Results at the ESGCT Gene therapy and gene editing plus other gene and genome-based therapeutics are the only treatments expected to lead to  miraculous cures. While genetic manipulation for the treatment of severe life-threatening diseases...

Read More

October 20, 2021

0

CRISPR Therapeutics to Present at the Citi 2024 Virtual Oncology Leadership Summit. See Also: CRISPR Therapeutics Advanced Steps

CRISPR Therapeutics Announcement Today, Feb. 15, 2024, CRISPR Therapeutics announced that members of its senior management team will present at the Citi 2024 Virtual Oncology Leadership Summit on Wednesday, Feb 21, 2024, at 1:00 p.m. ET. A live webcast of...

Read More

February 15, 2024

0

  • Previous
  • 1
  • 2
  • ...
  • 53
  • 54
  • 55
  • ...
  • 76
  • 77
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy